Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Gene therapy developer Voyager Therapeutics is angling for as much as $92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing debuts for life sciences companies. The company, a 2014 Fierce 15 honoree, is planning to offer about 4.7 million shares at between $15 and $17 each, setting aside another 703,125 shares for its underwriters to cover overalotments and trading under "VYGR" thereafter. Voyager's scheduled IPO comes amid an increasingly tough climate for biotech debutantes, as MyoKardia ($MYOK), Dimension Therapeutics ($DMTX), CytomX Therapeutics ($CTMX) and others have all priced at significant discounts over the past month. Voyager's lead program is a potential treatment for Parkinson's disease, and the company is working with Sanofi ($SNY) in a collaboration worth up to $845 million. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.